M
Marilyn A. Huestis
Researcher at National Institute on Drug Abuse
Publications - 40
Citations - 5451
Marilyn A. Huestis is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Poison control & Buprenorphine. The author has an hindex of 33, co-authored 40 publications receiving 4892 citations. Previous affiliations of Marilyn A. Huestis include Long Beach Memorial Medical Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Human Cannabinoid Pharmacokinetics
TL;DR: The cardiovascular and subjective effects of cannabis are blocked by rimonabant, the first CB-1 cannabinoid-receptor antagonist, documenting thatCB-1 receptors mediate these effects of smoked cannabis in humans.
Journal ArticleDOI
Neuropsychological Performance in Long-term Cannabis Users
Harrison G. Pope,Amanda J. Gruber,James I. Hudson,Marilyn A. Huestis,Deborah A. Yurgelun-Todd +4 more
TL;DR: Some cognitive deficits appear detectable at least 7 days after heavy cannabis use but appear reversible and related to recent cannabis exposure rather than irreversible andrelated to cumulative lifetime use.
Journal ArticleDOI
Cannabis Effects on Driving Skills
TL;DR: Evidence suggests recent smoking and/or blood THC concentrations 2-5 ng/mL are associated with substantial driving impairment, particularly in occasional smokers, and future cannabis-and-driving research should emphasize challenging tasks, such as divided attention, and include occasional and chronic daily cannabis smokers.
Journal ArticleDOI
Oral Fluid Testing for Drugs of Abuse
TL;DR: This review outlines OF testing advantages and limitations, and the progress in OF that has occurred in collection, screening, confirmation, and interpretation of cannabinoids, opioids, amphetamines, cocaine, and benzodiazepines.
Journal ArticleDOI
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.
Hendrée E. Jones,Rolley E. Johnson,Donald R. Jasinski,Kevin E. O'Grady,Christian A. Chisholm,Robin E. Choo,Michael Crocetti,Robert A. Dudas,Cheryl Harrow,Marilyn A. Huestis,Lauren M. Jansson,Michael E. Lantz,Barry M. Lester,Lorraine Milio +13 more
TL;DR: Results suggest that buprenorphine is not inferior to methadone on outcome measures assessing NAS and maternal and neonatal safety when administered starting in the second trimester of pregnancy.